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background: Prior studies have suggested that women may have greater benefit from cardiac resynchronization therapy defibrillators (CRT-D) than 
men. We compared long term mortality of CRT-D patients by sex, QRS morphology and duration.
Methods: We used survival curves and covariate adjusted hazard ratios (HR) to assess mortality by sex (using social security death index) in 
31,892 CRT-D recipients in the NCDR® ICD registry™ from 2006-2009 with up to 5 years follow-up. Patients were grouped by left bundle branch 
block (LBBB) and 10 ms increments in QRS duration.
results: Among CRT-D patients with LBBB, women had a 21% lower mortality risk than men (HR=0.79 [95% CI 0.74 - 0.84]) and longer QRS 
duration was associated with better survival in both sexes. Women with QRS 140-149 had 27% lower mortality than those with QRS 120-129, 
while this difference was 18% in men (Figure). Above 150 ms, the lower mortality risk was similar between sexes (32-39% for women and 34-42% 
for men). In CRT-D patients without LBBB there was no difference in adjusted mortality risk between sexes (p=0.37) and no relation between QRS 
duration and mortality.
conclusion: Among LBBB patients undergoing CRT-D, mortality risk is lower in women than men while there is no risk difference in non-LBBB. 
Furthermore, longer QRS duration is associated with better survival in LBBB patients only. This favorable prognosis appears to plateau above 140 ms 
in women and 150 ms in men. Further studies should include a non-CRT comparator group to confirm these findings.
 
